Drug · Monoclonal Antibody

Ipilimumab

CI-DRUG-00000309Explore in graph →NCIt C2654 CHEMBL1789844 CIViC Approved

Regulatory

Approvals (30)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory1 approval record · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as YERVOY (DIN 02379384) under ATC L01FX04 IPILIMUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 8, 2012	health-canada-dpd

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 2 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	200	78	63	667	30	CA, EU, US	Mar 25, 2011	2001-10
Malignant Kidney Neoplasm	Approved	Phase 4	35	20	8	60	1	US	Mar 25, 2011	2003-02
Malignant Lung Neoplasm	Approved	Phase 3	24	7	13	78	2	US	Mar 25, 2011	2002-03
Cutaneous Melanoma	Approved	Phase 3	11	3	3	25	1

Curated evidence

Clinical evidence (8)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–8 of 8 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
High2
Ipilimumab + Lenvatinib

Clinical trials

Trials with this intervention (681)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 681 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05112601	Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma	recruiting	Phase 2	81	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT07227012	Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

Molecule

Record

Kind: Monoclonal Antibody
Mechanism: Cytotoxic T-lymphocyte protein 4 inhibitor
Targets: 1 gene
UNII: 6T8C155666
Aliases: Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX010, MDX-010 MDX-CTLA4, MDX-101, MDX-CTLA-4, MDX-CTLA4, Yervoy, YERVOY

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (4)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01FX04	IPILIMUMAB
DIN (Health Canada)	02379384	YERVOY
DPD drug code